Key result
Targeting CD36 shows promise for atheroinflammatory disease by reducing atherosclerosis and thrombus formation.
Answers are grounded in this paper and cite their sources.
The CD36 scavenger receptor recognizes oxidized low-density lipoprotein (LDL) and cell-derived microparticles. It is expressed on macrophages and platelets and is a mediator of both atherogenesis and thrombosis. Macrophages from CD36-null mice have a defect in foam cell formation in response to exposure to oxidized LDL, and CD36-null mice fed an atherogenic Western diet have significantly less atherosclerosis than their wild-type counterparts. On platelets, CD36 recognition of oxidized LDL contributes to their activation and provides a mechanistic link between hyperlipidemia, oxidant stress, and the prothrombotic state. Cell-derived microparticles are also major ligands for CD36 and contribute to thrombus formation in a CD36-dependent manner even in the absence of hyperlipidemia. CD36 deficiency in mice is associated with inhibition of thrombus formation and with a reduction in microparticle accumulation in thrombi. Targeting CD36 is a promising avenue for the treatment of atheroinflammatory disorders.
No takes yet. Share an insight, caveat, or question.
Roy L. Silverstein (2009) conducted a review in Atherosclerosis and arterial thrombosis. CD36 deficiency or targeting vs. Wild-type was evaluated on Atherosclerosis and thrombus formation. Targeting the CD36 scavenger receptor is a promising avenue for treating atheroinflammatory disorders, as CD36 deficiency in mice reduces atherosclerosis and inhibits thrombus formation.
Synapse has enriched 10 related papers. Consider them for comparative context: